Corpus Intelligence IC Memo — SANTA CLARA VALLEY MEDICAL CENTER 2026-04-26 05:29 UTC
IC Memo — SANTA CLARA VALLEY MEDICAL CENTER
Investment Committee Memorandum | CA | 805 beds | Grade C | EBITDA uplift $187.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SANTA CLARA VALLEY MEDICAL CENTER

CCN 050038 | SANTA CLARA, CA | 805 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SANTA CLARA VALLEY MEDICAL CENTER is a 805-bed large academic medical center in SANTA CLARA, CA with $2.55B in net patient revenue and a -29.4% operating margin. The hospital serves a payer mix of 17.8% Medicare, 14.8% Medicaid, and 67.4% commercial.

Thesis: Undervalued. Our ML models identify $187.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -29.4% to -22.0% (+736bps).

Net Revenue HCRIS$2.55B
Current EBITDA COMPUTED$-750.4M
Operating Margin COMPUTED-29.4%
Occupancy HCRIS65.7%
Revenue / Bed COMPUTED$3.2M
Net-to-Gross HCRIS30.2%
Distress Probability ML46.2%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
34
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -29.4% places it below the state median. Among 34 size-comparable peers (402-1610 beds), the median margin is -4.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (402-1610), prioritizing same-state peers. 34 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SANTA CLARA VALLEY MEDICAL CEN (Target)CA805$2.55B-29.4%
STANFORD HEALTH CARECA657$6.76B3.7%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
CEDARS-SINAI MEDICAL CENTERCA908$3.92B-5.5%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
RONALD REAGAN UCLACA446$2.62B-6.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
COMMUNITY REGIONAL MEDICAL CENCA783$1.47B-10.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $187.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$53.6M+210bp18mo
Cost to Collect4.5%2.5%$51.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$50.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$31.0M+122bp9mo
Clean Claim Rate88.0%96.0%$1.6M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$53.6M
Cost to Collect
$51.0M
Denial Rate Reduction
$50.5M
A/R Days Reduction
$31.0M
Clean Claim Rate
$1.6M
Total EBITDA Uplift$187.8M
Current EBITDA$-750.4M
+ RCM Uplift+$187.8M
Pro Forma EBITDA$-562.6M
Current Margin-29.4%
Pro Forma Margin-22.0%
WC Released (1x)$97.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-1.15B$-3.07B0.00x-100.0%
Base (11x exit)10.0x11.0x$-1.15B$-3.75B0.00x-100.0%
Bull Case9.0x11.0x$-1.04B$-3.51B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.04B$-4.13B0.00x-100.0%
Bear Case11.0x10.0x$-1.27B$-3.64B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-1.27B$-4.41B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 34 hospitals with 402-1610 beds
  • Same-state prioritization (n=35)
  • Comp margins: P25=-10.3% / P50=-4.5% / P75=4.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.